RPC
VRTX icon

Rossmore Private Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Rossmore Private Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6
Closed -$899 – 399
2017
Q4 		$899 Buy
+6
New +$888 ﹤0.01% 441

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Rossmore Private Capital's VRTX Position: Q1 2018 in Review

Rossmore Private Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2018, closing a stake of 6 shares — an estimated $899 sold.

Rossmore Private Capital first reported a position in VRTX in Q4 2017 and held it in 1 quarter. The position peaked at $899 in Q4 2017. 680 funds tracked by Wall St. Rank hold VRTX as of Q1 2018.

  • Rossmore Private Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Rossmore Private Capital sold 6 Vertex Pharmaceuticals shares in Q1 2018, an estimated $899.
  • Rossmore Private Capital first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Rossmore Private Capital's Vertex Pharmaceuticals position peaked at $899 in Q4 2017.
  • 680 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2018.

Based on Rossmore Private Capital's 13F filing for Q1 2018, filed 4 May 2018.